NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $2.44 -0.16 (-6.15%) As of 11/20/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Anixa Biosciences Stock (NASDAQ:ANIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.40▼$2.5950-Day Range$2.44▼$3.3752-Week Range$2.32▼$5.46Volume355,052 shsAverage Volume199,494 shsMarket Capitalization$84.81 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Anixa Biosciences, Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners. The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets. Anixa has also pursued cancer-detection technologies through its Cchek platform. The company is led by Amit Kumar, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreANIX MarketRank™: 2.879145275425 of 5 starsAnixa Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 334th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAnixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnixa Biosciences has a consensus price target of $8.00, representing about 227.9% upside from its current price of $2.44.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Anixa Biosciences are expected to remain at ($0.31) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 5.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.36% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 2.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.66 News SentimentAnixa Biosciences has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Anixa Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows10 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Anixa Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $291,587.00 in company stock, which represents 0.3438% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $291,587.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIX Stock News HeadlinesAnixa Biosciences (NASDAQ:ANIX) Raised to "Hold" at Wall Street ZenNovember 21 at 1:06 AM | americanbankingnews.comAnixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine TechnologyNovember 19 at 8:45 AM | prnewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 21 at 1:00 AM | Weiss Ratings (Ad)Anixa Biosciences, Inc.: Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical TrialNovember 18 at 1:02 PM | finanznachrichten.deAnixa Biosciences, Inc. and Curia Announce Collaboration to Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical TrialNovember 18 at 1:02 PM | marketscreener.comMAnixa Biosciences (NASDAQ:ANIX) CEO Acquires $15,850.00 in StockNovember 3, 2026 | insidertrades.comInsider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Purchases 8,000 Shares of StockOctober 27, 2026 | insidertrades.comInsider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Acquires 8,000 Shares of StockOctober 23, 2026 | insidertrades.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.12 at the beginning of 2026. Since then, ANIX shares have decreased by 21.8% and is now trading at $2.44. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences Inc (NASDAQ:ANIX) released its earnings results on Wednesday, September, 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.00. Who are Anixa Biosciences' major shareholders? Top institutional shareholders of Anixa Biosciences include Marshall Wace LLP (2.33%), D.A. Davidson & CO., State Street Corp (0.46%) and CoreCap Advisors LLC (0.18%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Rocket One Inc. Common Stock (RKTO), Silo Pharma (SILO), Rocket Lab (RKLB) and Archer Aviation (ACHR). Company Calendar Last Earnings9/09/2026Today11/21/2026Next Earnings (Estimated)1/11/2027Fiscal Year End10/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANIX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year Founded1982Price Target and Rating Average Price Target for Anixa Biosciences$8.00 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+227.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.59% Return on Assets-67.80% Debt Debt-to-Equity RatioN/A Current Ratio8.55 Quick Ratio8.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book5.81Miscellaneous Outstanding Shares34,760,000Free Float25,586,000Market Cap$84.81 million OptionableOptionable Beta0.47 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ANIX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.